Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131I Treatment.
Phase of Trial: Phase II
Latest Information Update: 12 Mar 2016
At a glance
- Drugs Axitinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 12 Mar 2016 Results (pooled analysis of this and other study, n = 98) assessing exposure-response relationship presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 29 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (NCT00094055)
- 19 Oct 2005 New trial record.